<DOC>
	<DOCNO>NCT00003138</DOCNO>
	<brief_summary>RATIONALE : Erythropoietin colony-stimulating factor filgrastim stimulate production blood cell . It yet know whether erythropoietin without filgrastim effective standard blood transfusion reduce need transfusion patient anemia associate myelodysplastic syndrome . PURPOSE : Randomized phase III trial compare effectiveness erythropoietin without filgrastim standard blood transfusion reduce need transfusion patient anemia associate myelodysplastic syndrome .</brief_summary>
	<brief_title>Erythropoietin ( EPO ) +/- Filgrastim ( G-CSF ) v . Supportive Therapy Alone Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : - Compare benefit erythropoietin vs standard transfusion support reduce transfusion requirement patient myelodysplastic syndrome . - Compare clinical response , disease progression , survival patient treat regimen . - Compare toxicity regimens patient . - Evaluate whether add filgrastim ( G-CSF ) increase erythropoietin dose reduce transfusion requirement patient respond erythropoietin alone . - To compare benefit erythropoietin versus supportive care alone quality life ( QOL ) person myelodysplastic syndrome . OUTLINE : This randomize , control , multicenter , cross-over study . Patients stratify accord morphologic subtype ( refractory anemia [ RA ] v RA ring sideroblast vs RA excess blast ) , transfusion requirement ( yes v ) , prior erythropoietin treatment ( yes v ) , erythropoietin level ( least 200 mU/mL v le 200 mU/mL ) . Patients randomize one two treatment arm . - Arm I ( standard transfusion support ) : Patients receive red cell platelet transfusion symptoms maintain hematocrit level 25 % . Patients undergo bone marrow aspirate biopsy 4 month every year development acute leukemia completion study . Patients progressive disease may cross arm II least 4 month study 1 year time randomization . Patients cross receive erythropoietin alone . - Arm II ( Erythropoietin ) : Patients receive erythropoietin subcutaneously ( SC ) intravenously ( IV ) daily . Patients undergo bone marrow aspirate biopsy arm I . Treatment continue daily maximum 1 year . Patients stable progressive disease day 120 receive filgrastim ( G-CSF ) SC daily 3 day week erythropoietin SC daily 6 month . Patients response G-CSF lower-dose erythropoietin may proceed high dose erythropoietin . Quality life assess baseline , every 4 month study , study completion . Patients follow every 4 month 2 year , every 6 month 3 year , annually 5 year . ACTUAL ACCRUAL : A total 118 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>At least 18 year age Diagnosis myelodysplastic syndrome Refractory anemia ( RA ) RA ring sideroblast RA excess blast ( RAEB ) . RAEB patient must bone marrow blast count le 20 % le 5 % blast form peripheral blood Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 3 Platelet count great 30,000/mm^3 ( without platelet transfusion ) Hematocrit le 30 % ( pretransfusion ) Bilirubin le 3 mg/dL Blood urea nitrogen ( BUN ) less 40 mg/dL Creatinine le 2.0 mg/dL Prior epoetin alfa allow provided dosage le 30,000 unit per week le 1 month duration At least 1 month since prior erythropoietin At least 2 month since prior recombinant growth factor At least 2 month since prior chemotherapy malignancy autoimmune disease At least 2 week since prior androgen steroid treatment myelodysplastic syndrome RAEB transformation Chronic myelomonocytic leukemia Splenomegaly great 6 cm leave costal margin great 3 time normal size Uncontrolled hypertension Sensitivity E. coliderived protein Sensitivity epoetin alfa component ( e.g. , human albumin ) Documented iron deficiency . If marrow iron stain available , transferrin saturation must great 20 % ferritin great 100 ng/dL Active infection bleed Other uncontrolled malignancy Pregnant nursing . Fertile patient must use effective contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>anemia</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>filgrastim</keyword>
</DOC>